Sanofi-Synthelabo India, a part of pharma major Sanofi group, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding
Sanofi-Synthelabo India, a part of pharma major Sanofigroup, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding.
Through this investment, both Apollo and Sanofi would endeavour to expand Apollo Sugar Clinics to provide superior value to patients and doctors with an enhanced geographic reach, and provide high quality outcome oriented set of services.
Dr Prathap Reddy, chairman and founder, Apollo Hospitals Group, said, “I am confident that with this investment, Apollo Sugar Clinics is even better positioned to offer patients advanced care and counselling for diabetes management. I am delighted to be partnering with Sanofi, a global leader in diabetes management.” Business Standard
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…